BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 16897429)

  • 1. Prostate-derived Ets transcription factor (PDEF) downregulates survivin expression and inhibits breast cancer cell growth in vitro and xenograft tumor formation in vivo.
    Ghadersohi A; Pan D; Fayazi Z; Hicks DG; Winston JS; Li F
    Breast Cancer Res Treat; 2007 Mar; 102(1):19-30. PubMed ID: 16897429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate-derived Ets transcription factor as a favorable prognostic marker in ovarian cancer patients.
    Ghadersohi A; Odunsi K; Zhang S; Azrak RG; Bundy BN; Manjili MH; Li F
    Int J Cancer; 2008 Sep; 123(6):1376-84. PubMed ID: 18567002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-specific adenovirus-mediated PUMA gene transfer using the survivin promoter enhances radiosensitivity of breast cancer cells in vitro and in vivo.
    Wang R; Wang X; Li B; Lin F; Dong K; Gao P; Zhang HZ
    Breast Cancer Res Treat; 2009 Sep; 117(1):45-54. PubMed ID: 18791823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate-derived Ets transcription factor (PDEF) is a potential prognostic marker in patients with prostate cancer.
    Ghadersohi A; Sharma S; Zhang S; Azrak RG; Wilding GE; Manjili MH; Li F
    Prostate; 2011 Aug; 71(11):1178-88. PubMed ID: 21656828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MicroRNA-mediated inhibition of prostate-derived Ets factor messenger RNA translation affects prostate-derived Ets factor regulatory networks in human breast cancer.
    Findlay VJ; Turner DP; Moussa O; Watson DK
    Cancer Res; 2008 Oct; 68(20):8499-506. PubMed ID: 18922924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AR-PDEF pathway promotes tumour proliferation and upregulates MYC-mediated gene transcription by promoting MAD1 degradation in ER-negative breast cancer.
    Cao L; Xu C; Xiang G; Liu F; Liu X; Li C; Liu J; Meng Q; Jiao J; Niu Y
    Mol Cancer; 2018 Sep; 17(1):136. PubMed ID: 30217192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PDEF downregulates stathmin expression in prostate cancer.
    Sabherwal Y; Mahajan N; Helseth DL; Gassmann M; Shi H; Zhang M
    Int J Oncol; 2012 Jun; 40(6):1889-99. PubMed ID: 22378487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pdef expression in human breast cancer is correlated with invasive potential and altered gene expression.
    Feldman RJ; Sementchenko VI; Gayed M; Fraig MM; Watson DK
    Cancer Res; 2003 Aug; 63(15):4626-31. PubMed ID: 12907642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transcriptional regulation of p21/CIP1 cell cycle inhibitor by PDEF controls cell proliferation and mammary tumor progression.
    Schaefer JS; Sabherwal Y; Shi HY; Sriraman V; Richards J; Minella A; Turner DP; Watson DK; Zhang M
    J Biol Chem; 2010 Apr; 285(15):11258-69. PubMed ID: 20139077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate derived Ets transcription factor and Carcinoembryonic antigen related cell adhesion molecule 6 constitute a highly active oncogenic axis in breast cancer.
    Mukhopadhyay A; Khoury T; Stein L; Shrikant P; Sood AK
    Oncotarget; 2013 Apr; 4(4):610-21. PubMed ID: 23592399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor-specific RNAi targeting eIF4E suppresses tumor growth, induces apoptosis and enhances cisplatin cytotoxicity in human breast carcinoma cells.
    Dong K; Wang R; Wang X; Lin F; Shen JJ; Gao P; Zhang HZ
    Breast Cancer Res Treat; 2009 Feb; 113(3):443-56. PubMed ID: 18327707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced PDEF expression increases invasion and expression of mesenchymal genes in prostate cancer cells.
    Gu X; Zerbini LF; Otu HH; Bhasin M; Yang Q; Joseph MG; Grall F; Onatunde T; Correa RG; Libermann TA
    Cancer Res; 2007 May; 67(9):4219-26. PubMed ID: 17483333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigallocatechin-3 gallate induces growth inhibition and apoptosis in human breast cancer cells through survivin suppression.
    Tang Y; Zhao DY; Elliott S; Zhao W; Curiel TJ; Beckman BS; Burow ME
    Int J Oncol; 2007 Oct; 31(4):705-11. PubMed ID: 17786300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Upregulation of prostate-derived Ets factor by luteolin causes inhibition of cell proliferation and cell invasion in prostate carcinoma cells.
    Tsui KH; Chung LC; Feng TH; Chang PL; Juang HH
    Int J Cancer; 2012 Jun; 130(12):2812-23. PubMed ID: 21780100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survivin stable knockdown by siRNA inhibits tumor cell growth and angiogenesis in breast and cervical cancers.
    Li QX; Zhao J; Liu JY; Jia LT; Huang HY; Xu YM; Zhang Y; Zhang R; Wang CJ; Yao LB; Chen SY; Yang AG
    Cancer Biol Ther; 2006 Jul; 5(7):860-6. PubMed ID: 16861916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p62 overexpression in breast tumors and regulation by prostate-derived Ets factor in breast cancer cells.
    Thompson HG; Harris JW; Wold BJ; Lin F; Brody JP
    Oncogene; 2003 Apr; 22(15):2322-33. PubMed ID: 12700667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene expression profiling revealed survivin as a target of 3,3'-diindolylmethane-induced cell growth inhibition and apoptosis in breast cancer cells.
    Rahman KW; Li Y; Wang Z; Sarkar SH; Sarkar FH
    Cancer Res; 2006 May; 66(9):4952-60. PubMed ID: 16651453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of survivin reduces cell proliferation and induces apoptosis in human endometrial cancer.
    Ai Z; Yin L; Zhou X; Zhu Y; Zhu D; Yu Y; Feng Y
    Cancer; 2006 Aug; 107(4):746-56. PubMed ID: 16826583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of PDEF, a prostate-derived Ets factor is associated with aggressive phenotype of prostate cancer: regulation of MMP 9 by PDEF.
    Johnson TR; Koul S; Kumar B; Khandrika L; Venezia S; Maroni PD; Meacham RB; Koul HK
    Mol Cancer; 2010 Jun; 9():148. PubMed ID: 20550708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Downregulation of survivin by siRNA diminishes radioresistance of pancreatic cancer cells.
    Kami K; Doi R; Koizumi M; Toyoda E; Mori T; Ito D; Kawaguchi Y; Fujimoto K; Wada M; Miyatake S; Imamura M
    Surgery; 2005 Aug; 138(2):299-305. PubMed ID: 16153440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.